Loading clinical trials...
Loading clinical trials...
PTX35-001 A Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety of the Monoclonal Antibody PTX-35 in Patients With Advanced Solid Tumors Refractory to Standard of Care
Conditions
Interventions
PTX-35
Locations
3
United States
Providence Cancer Institute, Earle A. Chiles Research Institute
Portland, Oregon, United States
NEXT Oncology Austin
Austin, Texas, United States
Next Oncology
San Antonio, Texas, United States
Start Date
June 4, 2020
Primary Completion Date
November 2, 2022
Completion Date
June 15, 2023
Last Updated
March 12, 2024
NCT05720117
NCT06898450
NCT05719558
NCT05098132
NCT07477743
NCT07029399
Lead Sponsor
Pelican Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions